



Concert Pharmaceuticals to Present at The JMP Securities CNS Forum

August 18, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 18, 2020-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that James V. Cassella, Ph.D., Chief Development Officer, will be participating virtually in a fireside chat at The JMP Securities CNS Forum on August 19, 2020, at 10:00 a.m. ET. A live webcast of the event may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com.

About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert's [pipeline](#) of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200818005174/en/>

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.